CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL: CLINICAL CASE

  • Maryana Cherkes Department of Otolaryngology, Lviv City Children’s Clinical Hospital, Department of Operative Surgery with Topographic Anatomy, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine https://orcid.org/0000-0002-6553-974X
  • Puya Dehgani-Mobaraki Medical Director, Department Otorhinolaryngology and Head&Neck Surgery TThe Gubbio-Gualdo Tadino Hospital, Branca, President of the Association "Naso Sano" Onlus, Umbria, Regional Registry of Volunteer Activities, Corciano Lecturer at the Permanent Anatomical Dissection Laboratory at the University of Perugia, Italy, Front Line COVID19 Critical Care Alliance (FLCCC) https://orcid.org/0000-0001-8339-1868
  • Yuriy Gret Department of Anesthesiology and Intensive care Lviv Regional Clinical Hospital, Lviv, Ukraine https://orcid.org/0000-0003-0590-057X
Keywords: COVID-19, SARS-CoV-2, Coronavirus, pandemic, MATH , critical care management

Abstract

One of the principal precepts of bioethics that all students in healthcare are taught in school which is a fundamental principle throughout of medicine, is referred as the Latin phrase “primum non nocere”. This means that, in regard to therapeutic strategies, it is first of all necessary not to harm the patient and for this reason, among the possible treatments, the one that has fewer contraindications should always be privileged.
The current COVID-19 pandemic today counts more than 46 million cases and more than 1 million deaths worldwide.
While the vast majority of the scientific community is working tirelessly on the development of vaccines and control of the application of the results produced by the use of drugs in hospitalized patients, few studies have dealt with issues related to the concepts of prophylaxis and treatment of the early phase of the disease.
     Prophylaxis includes strategies capable, on the one hand, of containing the spread of SARS-CoV-2, on the other hand, mitigating the development of the immune system imbalance caused in severe forms of Coronavirus disease. That is why we present the MATH + clinical guidelines, which were created thanks to an international alliance of doctors from around the world and a description of the clinical case when the MATH + clinical guidelines were used.
      Medicine is a direction of human activity, which in its charity knows no boundaries, age restrictions, emotions and prohibitions. The doctor everywhere rushes to the rescue neglecting personal. That is why we strive to help all health workers, who are at the Front Line in the fight for the lives of COVID-19 critical patients.

Downloads

Download data is not yet available.

References

https://covid19criticalcare.com

https://www.puyadehgani.com/protocollod

https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1808462

https://covid19criticalcare.com/math-hospital-treatment/pdf-translations/

www.flccc.net

World Health Organization. Coronavirus disease 2019 (COVID-19): situation report −54

Mar 14 [cited 2020 sep 7]. https://www. who.int/docs/default-source/coronaviruse/situation-reports /20200314-sitrep-54-covid-19.pdf

Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with corona- virus disease 2019 (COVID-19) (March 20, 2020 Version). Crit Care Med. 2020;48(6):e440-e469.

https://doi.org/10.1097/CCM.0000000000004363

Cecconi M, Forni G, Mantovani A. Ten things we learned about COVID-19. Intensive Care Med. 2020;46:1590-1593.

https://doi.org/10.1007/s00134-020-06140-0

Li Y, Chen M, Cao H. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect. 2013;15(2):88-95.

https://doi.org/10.1016/j.micinf.2012.10.008

Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036-1045.e9.

https://doi.org/10.1016/j.cell.2020.04.026

Giamarellos-Bouboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3.

https://doi.org/10.1016/j.chom.2020.04.009

Dorward DA, Russell CD, Um IH, et al. Tissue-specific tolerance in fatal COVID-19. medRxiv. 2020.

https://doi.org/10.1101/2020.07.02.20145003

Du L, Kao RY, Zhou Y, et al. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007;359:174-179.

https://doi.org/10.1016/j.bbrc.2007.05.092

Yuriditsky E, Horowitz JM, Merchan C, et al. Thromboelastography profiles of critically ill patients with coronavirus disease 2019. Crit Care Med. 2020. DOI:10.1097/CCM.0000000000004471

https://doi.org/10.1097/CCM.0000000000004471

Draghici S, Nguyen TM, Sonna LA, et al. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. Nat Rev. 2020.

https://doi.org/10.1101/2020.05.06.20076687

Fadel R, Morrison AR, Vahia A, et al. Early course corticosteroids in hospitalized patients with COVID-19. medRxiv. 2020.

https://doi.org/10.1101/2020.05.04.20074609

Salton F, Confalonieri P, Santus P, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv. 2020.

https://doi.org/10.1101/2020.06.17.20134031

Chroboczek T, Lacoste M, Wackenheim C, et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. medRxiv. 2020.

https://doi.org/10.1101/2020.05.08.20094755

Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2020.

https://doi.org/10.1101/2020.06.17.20133579

Clinical management of COVID-19. Interim guidance. World Health Organization; 2020 May 27 [cited 2020 Oct 7]. https://www.who. int/publications/i/item/clinical-management-of-covid-19 WHO/ 2019-nCoV/clinical/2020.5

Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 (April 13th 2020, Version). Clin Infect Dis. 2020.

https://doi.org/10.1093/cid/ciaa478

Wilson KC, Chotirmall SH, Bai C, et al. COVID-19: interim guidance on management pending empirical evidence. From an American thoracic society-led international task force (April 3, 2020, Version)

cited 2020 Sep 7. https://www.thoracic.org/covid/covid-19- guidance.pdf

Villar J, Confalonieri M, Pastores SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome (ARDS) caused by COVID-19. Crit Care Expl. 2020;2:e0111.

https://doi.org/10.1097/CCE.0000000000000111

Tang C, Wang Y, Lv H, et al. Caution against corticosteroid-based COVID-19 treatment. Lancet. 2020;395(10239):1759-1760.

https://doi.org/10.1016/S0140-6736(20)30749-2

Russell CD, Millar JE, Bailllie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475.

https://doi.org/10.1016/S0140-6736(20)30317-2

Liu J, Zheng X, Huang Y, et al. Successful use of methylpredniso- lone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146 (2):325-327.

https://doi.org/10.1016/j.jaci.2020.05.021

RECOVERY Collaborative Group. Effect of dexamethasone in hospi- talized patients with COVID-19-preliminary report. N Engl J Med. 2020.

Li H, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A (H1N1) pdm09 viral pneumonia. Influenza Other Respi Viruses. 2017;11:345-354.

https://doi.org/10.1111/irv.12456

Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids. The Guangzhou experience. Chest. 2006;129: 1441-1452.

https://doi.org/10.1378/chest.129.6.1441

Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983;322(8357):995-997.

https://doi.org/10.1016/S0140-6736(83)90981-9

Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum DIs. 2002;61:718-722.

https://doi.org/10.1136/ard.61.8.718

Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42:15-31.

https://doi.org/10.1016/j.rdc.2015.08.002

Li H, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A (H1N1) pdm09 viral pneumonia. Influenza Other Respi Viruses. 2017;11:345-354.

https://doi.org/10.1111/irv.12456

Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids. The Guangzhou experience. Chest. 2006;129: 1441-1452.

https://doi.org/10.1378/chest.129.6.1441

Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983;322(8357):995-997.

https://doi.org/10.1016/S0140-6736(83)90981-9

Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum DIs. 2002;61:718-722.

https://doi.org/10.1136/ard.61.8.718

Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42:15-31.

https://doi.org/10.1016/j.rdc.2015.08.002

Oakley RH, Cidlowski JA. The biology of the glucocorticoid recep- tor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 2013;132:1033-1044.

https://doi.org/10.1016/j.jaci.2013.09.007

Marik PE, Vitamin C. An essential "stress hormone" during sepsis. J Thorac Dis. 2020;12(suppl 1):S84-S88.

https://doi.org/10.21037/jtd.2019.12.64

Marik PE. Vitamin C for the treatment of sepsis: the scientific rationale. Pharmacol Therapeut. 2018;189:63-70.

https://doi.org/10.1016/j.pharmthera.2018.04.007

Marik PE. Hydrocortisone, ascorbic acid and thiamine (HAT therapy) for the treatment of sepsis. Focus on ascorbic acid. Nutrients. 2018;10:1762.

https://doi.org/10.3390/nu10111762

Colunga. Biancatelli RM, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther. 2020;18:99-101.

https://doi.org/10.1080/14787210.2020.1706483

Colunga Biancatelli RM, Berrill M, Catravas JD, et al. Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2related disease (COVID-19). Front Immunol. 2020;11:1451.

https://doi.org/10.3389/fimmu.2020.01451

Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A. Therapeutic algorithm for use of melatonin in patients with COVID-19. Front Med 2020; 7:226.

https://doi.org/10.3389/fmed.2020.00226

Reiter RJ, Sharma R, Ma Q, Dominquez-Rodriguez A, Marik PE, Abreu-Gonzalez P. Melatonin inhibits COVID-19-induced cytokine storm by reversing aerobic glycolysis in immune cells: A mechanistic analysis. Medicine in Drug Discovery 2020; 6:100044.

https://doi.org/10.1016/j.medidd.2020.100044

Zhang R, Wang X, Ni L, Di X, Ma B. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020;250:117583.

https://doi.org/10.1016/j.lfs.2020.117583

May JM, Qu ZC. Ascorbic acid prevents oxidant-induced increases in endothelial permeability. Biofactors. 2011;37:46-50.

https://doi.org/10.1002/biof.134

May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal. 2013;19:2068-2083.

https://doi.org/10.1089/ars.2013.5205

Barabutis N, Ingoora V, Marik PE, et al. Hydrocortisone and ascorbic acid synergistically protect and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. Chest. 2017;152:954-962.

https://doi.org/10.1016/j.chest.2017.07.014

Howell AP, Parrett JL, Malcom DR. Impact of high-dose intravenous vitamin C for treatment of sepsis on point-of-care blood glucose readings. J Diabetes Sci Technol. 2019;193229681988963. DOI:10.1177/1932296819889638

https://doi.org/10.1177/1932296819889638

Stephenson E, Hooper MH, Marik PE. Vitamin C and point of care glucose measurements: A retrospective, observational study [Abstract]. Chest. 2018;154(suppl.):255a.

https://doi.org/10.1016/j.chest.2018.08.232

Marik PE. Is intravenous Vitamin C contraindicated in patients with G6PD deficiency? Crit Care. 2019;23:109.

https://doi.org/10.1186/s13054-019-2397-6

Vatsalya V, Li F, Frimodig J, Gala KS, Srivastava S, Kong M. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: Thiamine efficacy and safety, In-vitro evidence and pharmacokinetic profile. medRxiv 2020.

https://doi.org/10.1101/2020.08.23.20177501

Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C and Thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. Chest 2017; 151:1229-38.158

https://doi.org/10.1016/j.chest.2016.11.036

Iglesias J, Vassallo AV, Patel V, Sullivan JB, Cavanaugh J, Elbaga Y. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis. Chest 2020; 158:164-74

https://doi.org/10.1016/j.chest.2020.02.049

Collie JT, Greaves RF, Jones OA, et al. Vitamin B1 in critically ill patents: needs and challenges. Clin Chem Lab Med. 2017;55:1652-1668.

https://doi.org/10.1515/cclm-2017-0054

Cruickshank AM, Telfer AB, Shenkin A. Thiamine deficiency in the critically ill. Intensive Care Med. 1988;14:384-387.

https://doi.org/10.1007/BF00262893

Donnino MW, Carney E, Cocchi MN, et al. Thiamine deficiency in critically ill patients with sepsis. J Crit Care. 2010;25:567-581.

https://doi.org/10.1016/j.jcrc.2010.03.003

Donnino MW, Andersen LW, Chase M, et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: A pilot study. Crit Care Med. 2016;44:360-367.

https://doi.org/10.1097/CCM.0000000000001572

Crook MA, Sriram K. Thiamine deficiency: the importance of recog- nition and prompt management. Nutrition. 2014;30:953-954.

https://doi.org/10.1016/j.nut.2014.03.003

O'Keeffe ST, Tormey WP, Glasgow R, et al. Thiamine deficiency in hospitalized elderly patients. Gerontology. 1994;40:18-24.

https://doi.org/10.1159/000213570

Pepersack T, Garbusinski J, Robberecht J, et al. Clinical relevance of thiamine status amongst hospitalized elderly patients. Gerontology. 1999;45:91-101.

https://doi.org/10.1159/000022070

Zhang F, Masania J, Anwar A, et al. The uremic toxin oxythiamine causes functional thiamine deficiency in end-stage renal disease by inhibiting transketolase activity. Kidney Int. 2016;90:396-403.

https://doi.org/10.1016/j.kint.2016.03.010

de Andrade JA, Gayer CR, Nogueira NP, et al. The effect of thiamine deficiency on inflammation, oxidative stress and cellular migration in an experimental model of sepsis. J Inflamm. 2014;11:11.

https://doi.org/10.1186/1476-9255-11-11

Beltramo E, Berrone E, Buttiglieri S, et al. Thiamine and benfotia- mine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev. 2004;20: 330-336.

https://doi.org/10.1002/dmrr.470

Hazell AS, Faim S, Wertheimer G, et al. The impact of oxidative stress in thiamine deficiency: A multifactorial targeting issue. Neurochem Int. 2013;62:796-802.

https://doi.org/10.1016/j.neuint.2013.01.009

Lee CY, Jan WC, Tsai PS, Huang CJ. Magnesium sulfate mitigates acute lung injury in endotoxemia rats. JTrauma 2011; 70:1177-85.

https://doi.org/10.1097/TA.0b013e31820ca695

Tan CW, Ho LP, Kalimuddin S, Cherng BP, Teh YE. Cohort study to evaluate effect of vitamin D, magnesium, and vitamin b12 in combination on severe outcome progression in older patients with coronavirus (COVID-19). Nutrition 2020; 80:111017.

https://doi.org/10.1016/j.nut.2020.111017

Peake RW, Godber IM, Maguire D. The effect of magnesium admin- istration on erythrocyte transketolase activity in alcoholic patients treated with thiamine. Scott Med J. 2013;58:139-142.

https://doi.org/10.1177/0036933013496944

Zieve L. Influence of magnesium deficiency on the utilization of thiamine. Ann New York Acad Sci. 1969;162:732-743.

https://doi.org/10.1111/j.1749-6632.1969.tb13005.x

Marik PE, Varon J. Sepsis, delirium and long-term cognitive dys- function: prevention with the combination of vitamin C, hydrocor- tisone and thiamine. Curr Resp Med Rev. 2018;14:23-28.

https://doi.org/10.2174/1573398X14666180430145142

Juel J, Pareek M, Langfrits CS, et al. Anaphylactic shock and cardiac arrest caused by thiamine infusion. BMJ Case Rep. 2013;2013(jul12 1):bcr2013009648-bcr2013009648.

https://doi.org/10.1136/bcr-2013-009648

Wrenn KD, Slovis CM. Is intravenous thiamine safe? Am J Emerg Med. 1992;10:165.

https://doi.org/10.1016/0735-6757(92)90054-2

Trigonis RA, Holt DB, Yuan R, et al. Incidence of venous throm- boembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation. Crit Care Med. 2020. DOI:10.1097/CCM.0000000000004472

https://doi.org/10.1097/CCM.0000000000004472

Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospec- tive cohort study. Intensive Care Med. 2020;46:1089-1098.

https://doi.org/10.1007/s00134-020-06062-x

Klok FA, Kruip MJ, van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020.

https://doi.org/10.1016/j.thromres.2020.04.041

Dayer MR Coronavirus (2019-nCoV) deactivation via spike glyco- protein shielding by old drugs, bioinformatic study. Preprints. 2020. 60. Kwon PS, Oh H, Kwon SJ, et al. Sulphated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov. 2020;6:50.

https://doi.org/10.20944/preprints202005.0020.v1

While D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020.

https://doi.org/10.1007/s11239-020-02196-3

Tomasa-Irriguible TM, Martinez-Vega S, Mor-Marco E, et al. Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance! Crit Care. 2020;24:325.

https://doi.org/10.1186/s13054-020-03058-3

Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18:1320-1323.

https://doi.org/10.1111/jth.14871

Freedberg DE, Conigliaro J, Sobieszczyk ME, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. medRxiv. 2020.

https://doi.org/10.1053/j.gastro.2020.05.053

Jehi L, Ji X, Milinovich A, et al. Individualizing risk prediction for positive COVID-19 testing. Results from 11,672 patients. Chest. 2020. DOI:10.1016/j.chest.2020.05.580

https://doi.org/10.1016/j.chest.2020.05.580

Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.

https://doi.org/10.1016/j.cmet.2020.06.015

Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24:429.

https://doi.org/10.1186/s13054-020-03154-4

Merzon E, Tworowski D, Gorohovski A, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infec- tion: an Israeli population-based study. Faseb J. 2020.

https://doi.org/10.1101/2020.07.01.20144329

Rhodes JM, Subramanian S, Laird E, et al. Editorial: low population mortality from COVID-19 in countries south of 35 degrees north - supports vitamin D as a factor determining severity. Aliment Pharmacol Ther 2020;(in press).

https://doi.org/10.1111/apt.15777

Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Resp Med 2018; 6:691-8.

https://doi.org/10.1016/S2213-2600(18)30177-2

- Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Research Square 2020.

https://doi.org/10.21203/rs.3.rs-56210/v1

-Kow CS, Hasan SS. Meta-analysis of effectiveness of statins in patients with severe COVID-19. Am J Cardiol 2020.

https://doi.org/10.1016/j.amjcard.2020.08.004

-Tan WY, Young BE, Lye DC, Chew DE, Dalan r. Statin use is assocaited with lower disease severity in COVID-19 infection. Nature Research 2020

https://doi.org/10.1038/s41598-020-74492-0

Daneshkhah A, Eshein A, Subramanian H. The role of vitamin D in suppressing cytokine storm of COVID-19 patients and associated mortality. medRxiv. 2020.

https://doi.org/10.1101/2020.04.08.20058578

Jiang P, Lv Q, Lai T. Does hypomagnesemia impact on the outcome of patients admitted to the intensive care unit? A systematic review and meta-analysis. Shock. 2019;47(3):288-295.

https://doi.org/10.1097/SHK.0000000000000769


Abstract views: 606
PDF Downloads: 491
Published
2020-09-27
How to Cite
1.
Cherkes M, Dehgani-Mobaraki P, Gret Y. CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL: CLINICAL CASE. Proc Shevchenko Sci Soc Med Sci [Internet]. 2020Sep.27 [cited 2021Sep.18];62(2). Available from: https://mspsss.org.ua/index.php/journal/article/view/342
Section
CLINICAL PRACTICE GUIDELINES AND RECOMMENDATIONS